ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "glucocorticoids"

  • Abstract Number: 1946 • 2012 ACR/ARHP Annual Meeting

    Effect of Immunosuppressive Treatment On Gene Expression in Patients with Polymyositis and Dermatomyositis

    Ingela M. Loell1, Yi-Wen Chen2, Marina Korotkova3, Kanneboyina Nagaraju2 and Ingrid E. Lundberg4, 1Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, 2Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC, 3Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) muscle tissue is characterized by infiltrating T cells, macrophages and dendritic cells, as well as cytokines and chemokines. In…
  • Abstract Number: 1696 • 2012 ACR/ARHP Annual Meeting

    Quantitative Evaluation of Dermal Atrophy by High-Resolution Ultrasonography, Comparing Between Patients Under Long-Term Treatment with Prednisolone or Methylprednisolone

    Tim Pottel1, Christoph Schäfer2 and Gernot Keyßer2, 1Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06114 Halle (Saale), Germany, 2Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06120 Halle (Saale), Germany

    Background/Purpose: The katabolic effects of a systemic treatment with glucocorticoids can lead to a progressive atrophy of the skin. Clinical observation suggests a more pronounced…
  • Abstract Number: 1241 • 2012 ACR/ARHP Annual Meeting

    Glucocorticoid use Is associated with increase in HDL in Rheumatoid Arthritis Patients

    Lisa L. Schroeder1, Xiaoqin Tang2, Mary Chester M. Wasko3 and Androniki Bili4, 1Rheumatology, Geisinger Health System, Danville, PA, 2Biostatistics, Geisinger Center for Health Research, Danville, PA, 3West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA, 4Rheumatology, Geisinger Medical Center, Danville, PA

     Glucocorticoid use is associated with increase in HDL in Rheumatoid Arthritis PatientsBackground/Purpose: Atherogenic lipid profiles are common in active RA, with most common being decreased…
  • Abstract Number: 1146 • 2012 ACR/ARHP Annual Meeting

    Choice of Systemic JIA Treatment Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists

    Jennifer E. Weiss1, Esi M. Morgan DeWitt2, Timothy Beukelman3, Laura E. Schanberg4, Rayfel Schneider5 and Yukiko Kimura6, 1Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, 2Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Pediatrics, Duke University Medical Center, Durham, NC, 5Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Canada, 6Pediatric Rheumatology, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ

    Background/Purpose: Despite recent advances in identifying effective treatments for systemic Juvenile Idiopathic Arthritis (sJIA), many pediatric rheumatologists continue to use corticosteroids and methotrexate. The Childhood…
  • Abstract Number: 469 • 2012 ACR/ARHP Annual Meeting

    Intra Articular Injections in Patients with Rheumatoid Arthritis: Analyses From the Behandelstrategiën Study

    E. Gvozdenovic1, L. Dirven1, M. van den Broek2, Kh Han3, T.H.E. Molenaar4, R. Landewe5, W.F. Lems6 and C.F. Allaart1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Maasstad hospital, Rotterdam, Netherlands, 4Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 5Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 6Rheumatology, VU University medical center, Amsterdam, Netherlands

    Background/Purpose: Intra articular (IA) corticosteroid injections aim at amelioration of symptoms of local inflammation in rheumatoid arthritis (RA). Some patients also report a systemic effect.…
  • Abstract Number: 389 • 2012 ACR/ARHP Annual Meeting

    Oral Glucocorticoid Sparing Effects of Rituximab in Rheumatoid Arthritis Patients Who Have Switched from an Anti-TNF Therapy – an Administrative Claims Database Analysis

    Stephen Johnston1, Tripthi Kamath2, Nianwen Shi3, Robert Fowler3, Bong-Chul Chu3 and William Reiss4, 1Truven Health Analytics, Bethesda, MD, 2Genentech, South San Francisco, CA, 3Truven Health Analytics, Washington, DC, 4Genentech Inc., South San Francisco, CA

    Background/Purpose: The current treatment paradigm in RA is to attempt to decrease concomitant use of oral glucocorticoids (OGC). This study examined the OGC-sparing effects of…
  • Abstract Number: 367 • 2012 ACR/ARHP Annual Meeting

    Improved Fatigue-Related Quality of Life in CAPRA-2, a 12 Week Study of 5-Mg Modified (Delayed) Release Prednisone in Rheumatoid Arthritis

    Rieke Alten1, Amy Grahn2, Patricia Rice3 and Frank Buttgereit4, 1Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, 2Clinical Development, Horizon Pharma, Inc, Deerfield, IL, 3Statistics, CliniRx Research, Naperville, IL, 4Charité - Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Quality of life in rheumatoid arthritis (RA) patients can be improved by reducing the common symptom of fatigue caused by disease related factors such…
  • Abstract Number: 2352 • 2012 ACR/ARHP Annual Meeting

    Temporal Artery Biopsy Culture in Tridimensional Matrix. an in Vitro Model for Functional Studies in Giant-Cell Arteritis

    Marc Corbera Bellalta1, Ester Planas Rigol1, Ester Lozano1, Marco A. Alba2, Itziar Tavera-Bahillo1, Sergio Prieto-González1, Georgina Espígol Frigolé1, Montserrat Butjosa1, José Hernández-Rodríguez1, Ana García-Martínez3 and Maria C. Cid4, 1Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clinic University Barcelona, Barcelona, Spain, 2Systemic Autoimmune Diseases, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 3Department of Emergency Medicine, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 4Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

    Background/Purpose: GCA is the most frequent systemic vasculitis in Europe and North America. In spite of the initial response to glucocorticoid treatment more than 60%…
  • Abstract Number: 228 • 2012 ACR/ARHP Annual Meeting

    Simultaneous Initiating of Glucocorticoids and disease-Modifying Antirheumatic Drug Therapy in Polymyositis and Dermatomyositis Patients Results in the Opportunity to Taper Dosage of Glucocorticoids Early

    Kavish J. Bhansing1, Piet LCM Van Riel2, Sigrid Pillen3, Baziel G.M. van Engelen4 and Madelon C. Vonk5, 1Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3Neurology, Catharina Wilhemina Hospital, Nijmegen, Netherlands, 4Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

     Background/Purpose:             Glucocorticoids are the  cornerstone of therapy in patients with polymyositis (PM) and dermatomyositis (DM). However, side effects are common. Furthermore, glucocorticoids exhibits an…
  • Abstract Number: 2169 • 2012 ACR/ARHP Annual Meeting

    Short to Medium Term Safety of Glucocorticoid Therapy in Rheumatoid Arthritis: A Systematic Review and Dose-Response Analysis of Randomized Controlled Trials

    Simon Tarp1, Daniel Furst2, John R. Kirwan3, Maarten Boers4, Henning Bliddal5, Thasia Woodworth6, Else Marie Bartels7, Bente Danneskiold-Samsoe5, Lars Erik Kristensen8, Steffen Thirstrup9, Mette Rasmussen9, Marian Kaldas10 and Robin Christensen1, 1Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, 2Div of Rheumatology, UCLA Medical School, Los Angeles, CA, 3Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, 4Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, 5Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen F, Denmark, 6Leading Edge Clinical Research LLC, Florida, FL, 7Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen F, Denmark, 8Rheumatology, Skåen University Hospital, Lund University, Lund, Sweden, 9Institute for Pharmacology and Pharmacotherapy, University of Copenhagen, Copenhagen, Denmark, 10David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA

    Background/Purpose: Concerns regarding Adverse Effects (AEs) often dominate decisions on applying Glucocorticoid (GC) therapy. Evidence of AEs is mainly based on observational data without proper…
  • Abstract Number: 50 • 2012 ACR/ARHP Annual Meeting

    Human Chondrocyte Dedifferentiation Is Accompagnied by CD105 Endoglin Expression, ALK-1/Smad1/5 Phosphorylation and Leptin Production – Stimulation by Prednisolone and Aldosterone Through the Glucocorticoid Receptor

    Olivier Malaise1, Biserka Relic2, Mustapha Zeddou1, Edith Charlier1, Florence Quesada Calvo1, Sophie Neuville3, Dominique de Seny2 and Michel G. Malaise4, 1Department of Rheumatology, GIGA Research - University of Liège - CHU Liège, Liège, Belgium, 2Department of Rheumatology, GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, 3GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, 4Department of Rheumatology, University of Liège - CHU Liège, Liège, Belgium

    Background/Purpose:   Leptin, mainly produced by the adipose tissue including fat neighboring the joint, is considered as pro-inflammatory in osteoarthritis (OA). Normal cartilage does not…
  • Abstract Number: 2155 • 2012 ACR/ARHP Annual Meeting

    The Annualized Progression of Radiologic Damage in Placebo Arms of Rheumatoid Arthritis Trials Is Much Lower Than the Mean Annual Progression Since Disease Onset

    Jean-Marie Berthelot and Celine Cozic, Rheumatology Unit, Nantes University Hospital, Nantes, France

    Background/Purpose : A previous meta-analysis by Graudal and Jürgens (Arthritis Rheum. 2010;62:2852–63) challenged the belief that biologics better protect rheumatoid arthritis (RA) from joint destruction…
  • Abstract Number: 36 • 2012 ACR/ARHP Annual Meeting

    Role of FK506 Binding Protein 5 in Osteoclast Differentiation

    Miho Kimura1, Tatsuo Nagai2, Reiko Matsushita2, Atsushi Hashimoto3, Toshiyuki Miyashita4 and Shunsei Hirohata5, 1Rheumatology and Infectious diseases, Kitasato University School of Medicine, Sagamihara, Japan, 2Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, 3Department of Rheumatology, National Hospital Organization Sagamihara Hospital, Kanagawa, Japan, 4Molecular Genetics, Kitasato University School of Medicine, Sagamihara, 5Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan

    Background/Purpose: RA is a chronic, systemic inflammatory disease characterized by the destruction of bone in the joints. Moreover, it is well appreciated that systemic osteoporosis…
  • Abstract Number: 2085 • 2012 ACR/ARHP Annual Meeting

    T Cell-Mediated Murine Antigen-Induced Arthritis Is Resistant to Transgenic Disruption of Glucocorticoid Signaling in Osteoblasts and Osteocytes in Vivo

    Cornelia M. Spies1, Edgar Wiebe1, Jinwen W. Tu2, Aiqing Li2, Timo Gaber1, Dörte Huscher1, Markus J. Seibel2, Hong Zhou2 and Frank Buttgereit3, 1Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, 2Bone Research Program, ANZAC Research Institute, The University of Sydney, Concord, Australia, 3Charité - Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: The role of endogenous glucocorticoids (GC) in, and their contribution to the susceptibility and severity of rheumatoid arthritis remains inconclusive. We previously demonstrated that…
  • Abstract Number: 2077 • 2012 ACR/ARHP Annual Meeting

    IL-6 Blockade Augments the Anti-Inflammatory Effect without Increasing the Side Effects of Steroids in Collagen-Induced Arthritis

    Miho Suzuki1, Hiroto Yoshida2, Misato Hashizume1, Masashi Shiina2, Keisuke Tanaka1 and Yoshihiro Matsumoto1, 1Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

    Background/Purpose: Steroids are the main therapy for chronic inflammatory diseases. They are very effective, but induce many side effects, such as osteoporosis, making it important…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology